Benin Management Decreased Its Abbott Labs (ABT) Stake; HAMMERSON (HMSNF) Covered By 4 Bullish Analysts Last Week

November 20, 2017 - By Adrian Erickson

Among 6 analysts covering Hammerson (OTCMKTS:HMSNF), 4 have Buy rating, 1 Sell and 1 Hold. Therefore 67% are positive. Hammerson had 8 analyst reports since July 28, 2015 according to SRatingsIntel. The stock of HAMMERSON (OTCMKTS:HMSNF) earned “Neutral” rating by Goldman Sachs on Wednesday, January 25. The company was upgraded on Tuesday, July 28 by Numis Securities. The firm earned “Overweight” rating on Thursday, August 27 by Morgan Stanley. HSBC upgraded the shares of HMSNF in report on Wednesday, October 7 to “Buy” rating. The firm has “Buy” rating given on Tuesday, December 1 by Goldman Sachs. As per Tuesday, December 1, the company rating was initiated by Liberum Capital. The company was downgraded on Thursday, January 19 by Jefferies. The rating was downgraded by Jefferies on Monday, August 24 to “Hold”. See HAMMERSON (OTCMKTS:HMSNF) latest ratings:

Benin Management Corp decreased Abbott Labs (ABT) stake by 7.39% reported in 2017Q2 SEC filing. Benin Management Corp sold 7,900 shares as Abbott Labs (ABT)’s stock declined 3.42%. The Benin Management Corp holds 99,063 shares with $4.82M value, down from 106,963 last quarter. Abbott Labs now has $96.10 billion valuation. The stock declined 0.63% or $0.35 reaching $55.21 per share. About 1.29M shares traded. Abbott Laboratories (NYSE:ABT) has risen 15.90% since November 20, 2016 and is uptrending. It has underperformed by 0.80% the S&P500.

Benin Management Corp increased Schlumberger Ltd (NYSE:SLB) stake by 6,260 shares to 157,598 valued at $10.38M in 2017Q2. It also upped United Parcel Service Inc (NYSE:UPS) stake by 16,400 shares and now owns 55,211 shares. Spdr S&P 500 Etf Tr (SPY) was raised too.

Since June 15, 2017, it had 0 insider buys, and 1 sale for $26,482 activity. Watkin Jared also sold $26,482 worth of Abbott Laboratories (NYSE:ABT) on Thursday, June 15.

Analysts await Abbott Laboratories (NYSE:ABT) to report earnings on January, 24. They expect $0.73 EPS, up 12.31% or $0.08 from last year’s $0.65 per share. ABT’s profit will be $1.27 billion for 18.91 P/E if the $0.73 EPS becomes a reality. After $0.66 actual EPS reported by Abbott Laboratories for the previous quarter, Wall Street now forecasts 10.61% EPS growth.

Investors sentiment decreased to 0.88 in 2017 Q2. Its down 0.75, from 1.63 in 2017Q1. It dived, as 69 investors sold ABT shares while 545 reduced holdings. 102 funds opened positions while 441 raised stakes. 1.22 billion shares or 0.83% more from 1.21 billion shares in 2017Q1 were reported. Prentiss Smith Co stated it has 5.07% of its portfolio in Abbott Laboratories (NYSE:ABT). The Wisconsin-based Sii Invests Inc Wi has invested 0.04% in Abbott Laboratories (NYSE:ABT). Northside Capital Mngmt Ltd Limited Liability Company stated it has 9,503 shares or 0.2% of all its holdings. Moreover, Apg Asset Management Nv has 0.18% invested in Abbott Laboratories (NYSE:ABT). Advsrs Asset holds 0.1% or 123,135 shares. Wyoming-based Cypress Mgmt Limited Liability (Wy) has invested 0% in Abbott Laboratories (NYSE:ABT). Papp L Roy And Assocs, a Arizona-based fund reported 9,215 shares. Bancorpsouth Inc, Mississippi-based fund reported 6,943 shares. Cleararc owns 42,567 shares. Raymond James And Assocs invested 0.24% of its portfolio in Abbott Laboratories (NYSE:ABT). Mackenzie Fin Corp owns 0.01% invested in Abbott Laboratories (NYSE:ABT) for 19,679 shares. Stewart & Patten Llc reported 306,771 shares. 5,770 were reported by Atwood And Palmer Incorporated. Family Firm Incorporated accumulated 4,591 shares. Thomaspartners Inc stated it has 2.04% in Abbott Laboratories (NYSE:ABT).

Among 24 analysts covering Abbott Laboratories (NYSE:ABT), 14 have Buy rating, 0 Sell and 10 Hold. Therefore 58% are positive. Abbott Laboratories had 87 analyst reports since July 24, 2015 according to SRatingsIntel. As per Thursday, June 29, the company rating was reinitiated by Jefferies. RBC Capital Markets maintained the stock with “Buy” rating in Monday, June 26 report. The firm earned “Overweight” rating on Wednesday, October 7 by Barclays Capital. The stock has “Neutral” rating by Goldman Sachs on Friday, November 13. BMO Capital Markets maintained the stock with “Hold” rating in Monday, October 2 report. Wells Fargo maintained Abbott Laboratories (NYSE:ABT) rating on Thursday, September 28. Wells Fargo has “Buy” rating and $64.0 target. The stock of Abbott Laboratories (NYSE:ABT) has “Buy” rating given on Tuesday, June 14 by Jefferies. The stock of Abbott Laboratories (NYSE:ABT) has “Buy” rating given on Saturday, August 29 by BTIG Research. The stock of Abbott Laboratories (NYSE:ABT) earned “Market Perform” rating by BMO Capital Markets on Thursday, October 19. Jefferies maintained Abbott Laboratories (NYSE:ABT) on Tuesday, September 5 with “Buy” rating.

It is down 0.00% since November 20, 2016 and is . It has underperformed by 16.70% the S&P500.